RAIN
Price:
$1.21
Market Cap:
$44.01M
Rain Therapeutics Inc., a clinical-stage precision oncology company, engages in developing therapies that target oncogenic drivers in the United States. Its lead product candidate is milademetan, a small molecule oral inhibitor of mouse double minute 2, which is oncogenic in various cancers. The company is also developing milademetan which is in Phase 3 clinical trial for liposarcoma, Phase II clinical trial for solid tumors, and Phase II clinical trial for intimal sarcoma, as well as RAD52 which is in preclinical trials for tumors, including breast, ovarian, pancreatic, prostate, and other cancers. Rain Therapeutics Inc. was incorporated in 2017 and is headquartered in Newark, California.[Read more]
Industry
Biotechnology
IPO Date
2021-04-23
Stock Exchange
NASDAQ
Ticker
RAIN
According to Rain Therapeutics Inc.’s latest financial reports and current stock price. The company's current PE Ratio is -0.58. This represents a change of -72.77% compared to the average of -2.15 of the last 4 quarters.
The mean historical PE Ratio of Rain Therapeutics Inc. over the last ten years is -8.09. The current -0.58 PE Ratio has changed 622.69% with respect to the historical average. Over the past ten years (40 quarters), RAIN's PE Ratio was at its highest in in the June 2023 quarter at -0.49. The PE Ratio was at its lowest in in the March 2020 quarter at -16.39.
Average
-8.09
Median
-6.82
Minimum
-15.76
Maximum
-2.96
Discovering the peaks and valleys of Rain Therapeutics Inc. PE Ratio, unveiling quarterly and yearly fluctuations to gain insights into the company’s financial performance and market dynamics, offering valuable data for investors and analysts alike.
Maximum Annual Increase = 0%
Maximum Annual PE Ratio = -2.96
Minimum Annual Increase = -44.56%
Minimum Annual PE Ratio = -15.76
Year | PE Ratio | Change |
---|---|---|
2022 | -2.96 | -39.21% |
2021 | -4.86 | -44.56% |
2020 | -8.77 | -44.35% |
The current PE Ratio of Rain Therapeutics Inc. (RAIN) is greater than its 3-year, greater than its 5-year, and greater than its 10-year historical averages
3-year avg
-5.53
5-year avg
-8.09
10-year avg
-8.09
Rain Therapeutics Inc.’s PE Ratio is less than AVROBIO, Inc. (2.07), less than CohBar, Inc. (-0.20), less than Ocean Biomedical, Inc. (-0.17), less than Enveric Biosciences, Inc. (-0.36), greater than Elevation Oncology, Inc. (-0.93), less than Hepion Pharmaceuticals, Inc. (-0.15), greater than Zura Bio Limited (-9.00), less than eFFECTOR Therapeutics, Inc. (-0.00),
Company | PE Ratio | Market cap |
---|---|---|
2.07 | $5.24M | |
-0.20 | $1.25M | |
-0.17 | $33.96M | |
-0.36 | $4.53M | |
-0.93 | $36.94M | |
-0.15 | $4.20M | |
-9.00 | $230.86M | |
-0.00 | $188.18K |
One of the best ways to find valuable stocks to invest in is to build a custom made screener in your Excel or Google Sheets spreadsheet. This allows you to compare thousands of companies like Rain Therapeutics Inc. using the financials and key metrics that matter to you in a single view.
The easiest way to set this up is to use the Wisesheets add-on and set your spreadsheet like this:
Covering all these metrics from financial, data, dividend data, key metrics and more you can get all the data you want for over 50+ exchanges worldwide.
Get your free trial here.
The easiest way to analyze a company like Rain Therapeutics Inc. or any others is to create a spreadsheet model that automatically retrieves all of the stock data you need.
Using Wisesheets you can set up a spreadsheet model like this with simple spreadsheet formulas. If you change the ticker you can get all of the data automatically updated for you.
Whether you need live data, historical price data, financials, dividend data, key metrics, analyst estimates, or anything else...Wisesheets has you covered.
What is the PE Ratio?
How can you use the PE Ratio?
What is Rain Therapeutics Inc.'s PE Ratio?
How is the PE Ratio calculated for Rain Therapeutics Inc. (RAIN)?
What is the highest PE Ratio for Rain Therapeutics Inc. (RAIN)?
What is the 3-year average PE Ratio for Rain Therapeutics Inc. (RAIN)?
What is the 5-year average PE Ratio for Rain Therapeutics Inc. (RAIN)?
How does the current PE Ratio for Rain Therapeutics Inc. (RAIN) compare to its historical average?